MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.94
-0.33
-3.56%
After Hours: 8.83 -0.11 -1.23% 17:12 01/24 EST
OPEN
9.32
PREV CLOSE
9.27
HIGH
9.34
LOW
8.78
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
14.62
52 WEEK LOW
7.11
MARKET CAP
2.28B
P/E (TTM)
-5.6794
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FOLD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FOLD News

  • Amicus Therapeutics provides FY 2020 strategic and financial outlook
  • Seeking Alpha - Article.01/13 13:55
  • Amicus Therapeutics Sees Prelim. 2020 Galafold Revenue $250M-$260M; Sees FY19 Adj. Operating Expense $410M-$420M
  • Benzinga.01/13 12:09
  • Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
  • GlobeNewswire.01/13 12:00
  • 2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD)
  • Insider Monkey.01/10 16:43

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
More

Webull offers Amicus Therapeutics, Inc. (FOLD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.